Overview
An observatory for patients aged 18 years and over with Philadelphia chromosome positive (Ph+ or BCR::ABL1) acute lymphoblastic leukemia (ALL) and treated with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticosteroids and/or a monoclonal antibody.
Eligibility
Inclusion Criteria:
- Male or female patients ≥ 18 years
- Philadelphia chromosome or BCR::ABL1 positive acute lymphoblastic leukaemia
- Treatment with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticotherapy and/or a monoclonal antibody
Exclusion Criteria:
- Patients deceded and having previously refused data collection
- Not included in a prospective clinical trial


